1. Dose reductions, toxicities and survival in patients with excess weight undergoing adjuvant chemotherapy for colon and rectal cancers : individual patient data secondary analyses of consortium trials and causal inference modelling
- Author
-
Slawinski, Corinna, Renehan, Andrew, Barriuso, Jorge, and Guo, Hui
- Subjects
Mediation analysis ,Causal Inference ,Counterfactual ,Meta-analysis ,Individual Participant Data ,Colorectal cancer ,Survival ,Toxicity ,Adjuvant chemotherapy ,Obesity - Abstract
Introduction: Elevated body mass index (BMI) may be associated with reduced survival in nonmetastatic colorectal cancer (CRC). Whether this occurs directly, or indirectly through treatment-related mechanisms such as capping of adjuvant chemotherapy (ACT) doses and toxicity, is unclear. This thesis aimed to disentangle the effects of BMI, ACT adherence and toxicity on survival using individual participant data (IPD), causal mediation, and meta-analysis. Methods: Data from four randomised clinical ACT trials (MOSAIC, SCOT, CHRONICLE and PROCTOR-SCRIPT [five datasets – SCOT arms analysed individually]), with derivable BMI (at trial enrolment) cycle-level dosing and toxicity data were utilised from the OCTOPUS consortium. Dose capping was defined as < 95% of the expected (full BSA-based) cycle 1 dose. Two ACT adherence measures were calculated: average cumulative relative dose (ACRD: percentage of actual-to-expected cumulative dose (mg/m2 )) and average relative dose intensity (ARDI: percentage of actual-to-expected dose intensity [DI: cumulative dose/treatment duration (mg/m2/week)]). Directed acyclic graphs pre-defined putative causal pathways/confounders. The primary outcome was overall survival (OS). Trial level chemotherapy and toxicity data were summarised by BMI category (Chapters three and four). Two-stage random effects IPD metaanalyses were performed to assess BMI, adherence, toxicity, and survival relationships (Chapter five). Causal inference mediation analysis methods were explored, followed by metaanalysis of direct, indirect, and total effects from the mediation models (Chapter six). Results I (Chapter 3): A total of 7269 patients from five datasets demonstrated obesity incidence ranging 5.0%-22.8%. Cycle 1 dose capping rates increased with increasing BMI categories (ranging 29.6% to 62.2% of obese patients), with evidence of attrition of dosing differences across administered cycles (excluding MOSAIC). Subsequent cycle dose reductions and early discontinuation tended not to be associated with BMI. Overall, mean ARDI and ACRD were lowest amongst obese patients. Results II (Chapter 4): BMI did not appear to be associated with the occurrence of grade 3+ toxicity across the trials. However, there was a tendency for the incidence of neutropenia to reduce with increasing BMI. Additionally, the proportion of first grade 3+ toxicity episode occurring late increased with increasing BMI. However, results were limited by missing data. Results III (Chapter 5): BMI increments of 5kg/m2 were associated with increased dose capping odds (OR (95%CI): 2.70 (2.00, 3.64)) in addition to reduced ARDI (Coef. -1.08% (-1.44, -0.72)) and ACRD (Coef. -1.14% (-1.91, -0.38)), with no demonstrable BMI-grade 3+ toxicity relationship. Increments of 5% ARDI were significantly associated with reduced OS (HR 1.05 (1.01, 1.09)). Conversely, 5% ACRD increments were associated with improved OS (HR 0.94 (0.91, 0.96)), raising the possibility of a small adverse indirect effect of BMI via reduced ACRD. Grade 3+ toxicity was associated with reduced ACRD (-10.37% (-11.77, -8.97)) and reduced OS (HR 1.37 (1.17, 1.61)). The latter effects attenuated on adjusting for ACRD (HR 1.20 (1.02, 1.41)), suggesting partial mediation via ACRD. BMI 5kg/m2 increments were not associated with OS. Results IV (Chapter 6): Meta-mediation demonstrated no significant total effect (TE) of 5kg/m2 BMI increments on OS. However, a significant adverse natural indirect effect (NIE) was demonstrated via ACRD (1% reduction in mean survival time (MST)), with no natural direct effect (NDE). Furthermore, a significant TE of 5kg/m2 BMI increments on both ARDI and ACRD (1% reduction) was demonstrated, with no NIE mediated via toxicity. Finally, the TE of grade 3+ toxicity on OS was a 19% reduction in MST, partially mediated via ACRD (NIE and NDE demonstrated a 9% and 10% reduction in MST respectively). Conclusion: Elevated BMI did not influence survival from CRC despite modest under-dosing. However, results support full BSA-based dosing for CRC patients with a high BMI, without significant additional toxicity risks. Toxicity may contribute to poorer overall survival via pathways both including and excluding ACRD, and hence dosing decisions should account for other toxicity risk factors.
- Published
- 2022